Johnson & Johnson Reports Q3 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Johnson & Johnson (JNJ) Reports a Beat-and-Raise 3Q, Analyst Positive
October 19, 2021 7:53 AM EDTJohnson & Johnson (NYSE: JNJ) reported better-than-expected 3Q results today and left its vaccine guidance unchanged.
The company reported Q3 EPS of $2.60 to top the analyst estimate of $2.36. However, revenue for the quarter came in at $23.3 billion to miss the consensus estimate of $23.74 billion. The company left its COVID-19 vaccine sales target unchanged at $2.5... More
Johnson & Johnson (JNJ) Tops Q3 EPS by 24c, Raises FY Guidance
October 19, 2021 6:27 AM EDT(Updated - October 19, 2021 6:28 AM EDT)
Johnson & Johnson (NYSE: JNJ) reported Q3 EPS of $2.60, $0.24 better than the analyst estimate of $2.36. Revenue for the quarter came in at $23.3 billion versus the consensus estimate of $23.74 billion.
GUIDANCE:
Johnson & Johnson sees 2021 EPS of $9.77-$9.82,... More
